SCHEMBL8104136

SCHEMBL8104136

CC(=O)CCCCCCCc1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.71
RXFP1 Q9HBX9 1/20 0.71
ALDH1A1 P00352 1/20 0.70
ALOX5 P09917 3/20 0.62
HDAC1 Q13547 2/20 0.62
HDAC2 Q92769 2/20 0.62
CES1 P23141 4/20 0.61
FAAH O00519 4/20 0.61
HDAC3 O15379 1/20 0.59
MAPK1 P28482 1/20 0.59
ADRA1A P35348 1/20 0.59
HDAC4 P56524 1/20 0.59
SLC6A3 Q01959 1/20 0.59
SMN1; SMN2 Q16637 1/20 0.59
HDAC7 Q8WUI4 1/20 0.59
HDAC10 Q969S8 1/20 0.59
HDAC11 Q96DB2 1/20 0.59
HDAC8 Q9BY41 1/20 0.59
HDAC6 Q9UBN7 1/20 0.59
HDAC9 Q9UKV0 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19149704 1.00 MAPT (0.71) MAPTRXFP1ALDH1A1ALOX5HDAC1
SCHEMBL547835 1.00 MAPT (0.71) MAPTRXFP1ALDH1A1ALOX5HDAC1
SCHEMBL12040622 1.00 MAPT (0.71) MAPTRXFP1ALDH1A1ALOX5HDAC1
SCHEMBL5681573 1.00 MAPT (0.71) MAPTRXFP1ALDH1A1ALOX5HDAC1
SCHEMBL6213668 1.00 MAPT (0.71) MAPTRXFP1ALDH1A1ALOX5HDAC1
SCHEMBL24340640 1.00 MAPT (0.71) MAPTRXFP1ALDH1A1ALOX5HDAC1
SCHEMBL13498521 1.00 MAPT (0.71) MAPTRXFP1ALDH1A1ALOX5HDAC1
SCHEMBL2632727 1.00 MAPT (0.71) MAPTRXFP1ALDH1A1ALOX5HDAC1
SCHEMBL1105483 0.98 ALDH1A1 (0.73) MAPTRXFP1ALDH1A1ALOX5HDAC1
Formaldehyde SCHEMBL6456543 0.94 ALDH1A1 (0.68) MAPTRXFP1ALDH1A1ALOX5HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170196854-A1 USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS INTERVET INC. (US) 2017-07-13 US disclosed
US-9096524-B2 Anthelmintic agents and their use INTERVET INTERNATIONAL B.V. (NL) 2015-08-04 US disclosed
US-20130164325-A1 CERAMIDE-LIKE GLYCOLIPID-ASSOCIATED BACTERIAL VACCINES AND USES THEREOF ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2013-06-27 US disclosed
US-20130164325-A1 CERAMIDE-LIKE GLYCOLIPID-ASSOCIATED BACTERIAL VACCINES AND USES THEREOF ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) 2013-06-27 US disclosed
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE INTERVET INTERNATIONAL B.V. (NL) 2011-12-29 US disclosed
EP-1660507-B9 PROTEASOME INHIBITORS AND METHODS OF USING THE SAME CEPHALON INC (US) 2010-03-24 EP disclosed
US-6071899-A Azetidinone derivatives for the treatment of atherosclerosis SMITHKLINE BEECHAM P.L.C. (GB) 2000-06-06 US disclosed
US-5990102-A Substituted azetidin-2-ones for treatment of atherosclerosis SMITHKLINE BEECHAM P.L.C. (GB) 1999-11-23 US disclosed
EP-0799200-A1 SUBSTITUTED AZETIDIN-2-ONES FOR TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 1997-10-08 EP disclosed
EP-0788478-A1 AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 1997-08-13 EP disclosed
WO-1996019451-A1 SUBSTITUTED AZETIDIN-2-ONES FOR TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 1996-06-27 WO disclosed
WO-1996013484-A1 AZETIDINONE DERIVATIVES FOR THE TREATMENT OF ATHEROSCLEROSIS SMITHKLINE BEECHAM PLC (GB) 1996-05-09 WO disclosed
US-4131745-A ANTIDEPRESSANT AYERST, MCKENNA & HARRISON, LTD. (CA) 1978-12-26 US disclosed
US-4125541-A Aryl substituted ketones STERLING DRUG INC. (US) 1978-11-14 US disclosed
US-4125714-A Aryl substituted cycloalkanones STERLING DRUG INC. (US) 1978-11-14 US disclosed
US-4118511-A Aryloxy aminobutanols for alleviating symptoms of depression AYERST, MCKENNA & HARRISON LIMITED (CA) 1978-10-03 US disclosed
US-4071552-A Aryloxy aminobutanols, their preparation and use thereof AYERST MCKENNA AND HARRISON LTD. (CA) 1978-01-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319393-A1 ANTHELMINTIC AGENTS AND THEIR USE ACHE, ABCB11, MPO MAPT 1648/4885RXFP1 4117/4885ALDH1A1 864/4885
US-20170196854-A1 USE OF ANTHELMINTIC AGENTS AGAINST DIROFILARIA IMMITIS MPO, DHODH, DHX35 MAPT 2413/4885RXFP1 3756/4885ALDH1A1 1001/4885
US-20130164325-A1 CERAMIDE-LIKE GLYCOLIPID-ASSOCIATED BACTERIAL VACCINES AND USES THEREOF SGMS1, CERT1, SGMS2 MAPT 2071/4885RXFP1 3556/4885ALDH1A1 4502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.